<DOC>
	<DOCNO>NCT00621244</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics preliminary anti-leukemic anti-tumor activity LBH589B adult patient advance hematological malignancy</brief_summary>
	<brief_title>A Study Oral LBH589 Adult Patients With Advanced Hematological Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criterion : Adult patient ( ≥18 year old ) advance hematological malignancy relapse refractory standard therapy , standard therapy exist ; , consider inappropriate candidate standard therapy World Health Organization ( WHO ) performance status ≤ 2 Patients must meet protocolspecified hematologic nonhematologic laboratory value Patients must adequate liver renal function Exclusion criterion : Concurrent brain metastasis leukemic infiltration cerebrospinal fluid Peripheral neuropathy ≥ CTCAE grade 2 Unresolved diarrhea ≥ CTCAE grade 2 Concurrent severe and/or uncontrolled medical condition may compromise participation study , include impaired heart function clinically significant heart disease , impaired gastrointestinal function disease may significantly alter aborption LBH589 Female patient pregnant breast feed Patients willing use effective method birth control Patients take medication specify protocol prohibit administration combination LBH589 Patients another primary malignancy currently require active intervention currently clinically significant Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>HDAC inhibitor</keyword>
	<keyword>Oral</keyword>
	<keyword>LBH589</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Multiple myeloma</keyword>
</DOC>